Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.

ABSTRACT:

Background

Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant immunotherapy for melanoma.

Methods

In-depth interviews were conducted with physicians (medical oncologists, surgeons and dermatologists) and nurses managing patients with resected stage III melanoma at three Australian tertiary melanoma centres between July 2019 and March 2020. Factors considered regarding adjuvant immunotherapy were explored. Recruitment continued until data saturation and thematic analysis was undertaken.

Results

Twenty-five physicians and nurses, aged 28-6

SUBMITTER: Livingstone A 

PROVIDER: S-EPMC8434723 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature